GlassScriptPhysician profile
Shaz Siddiqi
NPI 1093750796
$18,834.50
in general payments reported to CMS, 2019-2025
32 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2021: $487 · 2022: $2,250 · 2023: $2,328 · 2024: $2,440 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,145 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,800 · Travel and Lodging: $498 · Education: $49.27 · Consulting Fee: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,144.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,800.00 |
| Travel and Lodging | $497.52 |
| Education | $49.27 |
| Consulting Fee | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $7,679.98 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $2,169.99 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,651.13 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,184.48 | 2019-2025 | Dupixent |
| Genzyme Corporation | $822.70 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $708.70 | 2022-2025 | Cuvitru, Takhzyro |
| Amgen INC. | $681.00 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $594.10 | 2021-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $460.65 | 2019-2025 | |
| Optinose US, INC. | $437.41 | 2019-2025 | |
| Kaleo, INC. | $410.28 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $392.01 | 2019-2025 | |
| Genentech USA, INC. | $263.11 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $202.91 | 2022-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $150.46 | 2021-2023 | Airduo Digihaler |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $146.04 | 2023-2025 | Hizentra, Andembry, Haegarda |
| Lilly USA, LLC | $127.03 | 2024-2025 | Taltz, Ebglyss |
| Alk-Abello, INC | $116.12 | 2021-2022 | |
| Incyte Corporation | $90.76 | 2022-2024 | Opzelura |
| Sanofi-Aventis U.S. LLC | $84.59 | 2021-2022 | |
| Leo Pharma INC. | $84.53 | 2023 | Adbry |
| Pharming Healthcare, INC. | $66.83 | 2021-2024 | Ruconest |
| Aimmune Therapeutics, INC. | $62.44 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $54.80 | 2023-2025 | Ryaltris |
| Galderma Laboratories, L.P. | $41.61 | 2025 | Nemluvio |
| Organon LLC | $31.24 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $29.12 | 2021-2022 | |
| Abbvie INC. | $25.45 | 2023 | Rinvoq |
| Blueprint Medicines Corporation | $24.65 | 2023 | Ayvakit |
| Octapharma USA, INC. | $21.08 | 2023 | Cutaquig |
| Adma Biomanufacturing LLC | $19.30 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaz Siddiqi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.